SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative cannabinoid-based formulations, announced that it has received both its Analytical Testing Licence and Research Licence from Health Canada in accordance with Canada’s Cannabis Act and Cannabis Regulations. The grant of these additional licenses follows the recent grant by Health Canada of ZYUS’ Standard Processing Licence for its Saskatoon-b

READ MORE: https://www.businesswire.com/news/home/20200211005358/en/ZYUS-Life-Sciences-Receives-Analytical-Testing-Research/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==